Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest announcement is out from NeuroPace ( (NPCE) ).
NeuroPace has announced the appointment of Scott Huennekens to its Board of Directors, a move that brings extensive expertise in management and investment to the company. The company also reported strong preliminary financial results for 2024, with significant revenue growth exceeding initial guidance, and progress on the NAUTILUS pivotal trial for the RNS System, indicating positive future prospects in the treatment of drug-resistant epilepsy.
More about NeuroPace
NeuroPace, Inc., based in Mountain View, California, is a medical device company focused on improving the lives of people with epilepsy. The company offers the RNS System, a brain-responsive platform that provides personalized treatment for drug-resistant epilepsy and has potential applications for other brain disorders.
YTD Price Performance: 7.25%
Average Trading Volume: 80,370
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $356.1M
For detailed information about NPCE stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- FuboTV (NYSE:FUBO) Lawsuit Faces New Challenge from DirecTV
- Tesla’s (NASDAQ:TSLA) Elon Musk Reveals AI Training Has Reached Its Limits
- Mario Gabelli Comes Back for Files in the Paramount (NASDAQ:PARA) Merger
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
